Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT04275414
Phase
PHASE2
Status
Completed

Conditions

  • Coronavirus Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The novel identified coronavirus (SARS-CoV-2) in 2019 causes an nationwide outbreak as well as public health crisis in China, and expands globally. Pulmonary edema is one of the most detrimental symptoms and usually presents in severe and critical coronavirus disease (COVID-19), resulting in dyspnea, acute lung injury (ALI) ,acute respiratory distress syndrome (ARDS), and even death. Recent evidence revealed higher levels of blood Vascular Endothelial Growth Factor (VEGF) in COVID-19 patients compared with healthy controls. VEGF is considered as the most potent vascular permeability inducers. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004 and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema.

Key Dates

First listed
Feb 19, 2020
Start date
Feb 15, 2020
Status verified
Feb 2020
Primary completion
Apr 5, 2020
Completion
May 2, 2020

Study Design

Enrollment
27 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab plus standard care
    Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.

Primary Outcome Measure

Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio [ Time Frame: 24 hours ]

Related Studies